Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis | Zendy

Esteban Ribera | Zendy; Carlos Azuaje | Zendy; Rosa María López | Zendy; Peré Domingo | Zendy; Adrián Curran | Zendy; Maria FeijooCid | Zendy; Leonor Pou | Zendy; Paquita Sánchez | Zendy; M. A. Sambeat | Zendy; J Colomer | Zendy; Josep Lluis Lopez-Colomes | Zendy; Manuel Crespo | Zendy; Vicenç Falcó | Zendy; I Ocaña | Zendy; Albert Pahissa | Zendy

Open Access

Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis

Author(s) -

Esteban Ribera,

Carlos Azuaje,

Rosa María López,

Peré Domingo,

Adrián Curran,

Maria FeijooCid,

Leonor Pou,

Paquita Sánchez,

M. A. Sambeat,

J Colomer,

Josep Lluis Lopez-Colomes,

Manuel Crespo,

Vicenç Falcó,

I Ocaña,

Albert Pahissa

Publication year - 2007

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkl552

Subject(s) - saquinavir , ritonavir , rifampicin , pharmacokinetics , medicine , tuberculosis , pharmacology , human immunodeficiency virus (hiv) , virology , ethambutol , drug interaction , viral load , antiretroviral therapy , pathology

To assess plasma steady-state pharmacokinetics (PK) of rifampicin, isoniazid, saquinavir and ritonavir in HIV and tuberculosis (TB) co-infected patients, and investigate potential interactions between TB drugs and protease inhibitors (PIs).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research